Pharmaceuticals - Global Group of Eight (G8) Industry Guide

NEW YORK, Jan. 9, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pharmaceuticals - Global Group of Eight (G8) Industry Guide

http://www.reportlinker.com/p0191857/Pharmaceuticals---Global-Group-of-Eight-G8-Industry-Guide.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical

Pharmaceuticals - Global Group of Eight (G8) Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals industry in each of the G8 (United States, Canada, Germany, France, United Kingdom, Italy, Russia and Japan) countries. The report includes easily comparable data on market value, volume, segmentation and market share, plus full five year market forecasts. It examines future problems, innovations and potential growth areas within the market.

Scope of the Report * Contains an executive summary and data on value, volume and segmentation

* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies

* Incorporates in-depth five forces competitive environment analysis and scorecards

* Compares data from the US, Canada, Germany, France, UK, Italy, Russia and Japan, alongside individual chapters on each country. .

* Includes a five-year forecast of the industry

Highlights The G8 countries contributed $534.8 billion in 2011 to the global pharmaceuticals industry, with a compound annual growth rate (CAGR) of 3.3% between 2007 and 2011. The G8 countries are expected to reach a value of $600.2 billion in 2016, with a CAGR of 2.3% over the 2011-16 period.

Among the G8 countries, the US holds the major share of the pharmaceuticals industry. It accounted for a share of 49.1% in 2011.

Among the G8 nations, the US is the leading country in the pharmaceuticals industry, with market revenues of $262.7 billion in 2011.

The US is expected to lead the pharmaceuticals industry in the G8 nations with a value of $299.5 billion in 2016.

Why you should buy this report

* Spot future trends and developments

* Inform your business decisions

* Add weight to presentations and marketing materials

* Save time carrying out entry-level research

Market Definition The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.

Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors).

Any currency conversions used in the production of this report have been calculated at constant 2011 annual average exchange rates.

TABLE OF CONTENTSIntroduction 16What is this report about? 16Who is the target reader? 16How to use this report 16Definitions 16Group of Eight (G8) Pharmaceuticals Industry Outlook 17Pharmaceuticals in Canada 21Market Overview 21Market Data 22Market Segmentation 23Market outlook 25Five forces analysis 26Macroeconomic indicators 34Pharmaceuticals in France 36Market Overview 36Market Data 37Market Segmentation 38Market outlook 40Five forces analysis 41Macroeconomic indicators 49Pharmaceuticals in Germany 51Market Overview 51Market Data 52Market Segmentation 53Market outlook 55Five forces analysis 56Macroeconomic indicators 64Pharmaceuticals in Italy 66Market Overview 66Market Data 67Market Segmentation 68Market outlook 70Five forces analysis 71Macroeconomic indicators 79Pharmaceuticals in Japan 81Market Overview 81Market Data 82Market Segmentation 83Market outlook 85Five forces analysis 86Macroeconomic indicators 94Pharmaceuticals in Russia 96Market Overview 96Market Data 97Market Segmentation 98Market outlook 100Five forces analysis 101Macroeconomic indicators 109Pharmaceuticals in The United Kingdom 111Market Overview 111Market Data 112Market Segmentation 113Market outlook 115Five forces analysis 116Macroeconomic indicators 124Pharmaceuticals in The United States 126Market Overview 126Market Data 127Market Segmentation 128Market outlook 130Five forces analysis 131Macroeconomic indicators 139Company Profiles 141Leading companies 141Appendix 183Methodology 183

LIST OF TABLES

Table 1: G8 pharmaceuticals industry, revenue($bn), 2007-16 16

Table 2: G8 Pharmaceuticals industry, revenue by country (%), 2011 17

Table 3: G8 pharmaceuticals industry, revenue by country ($bn), 2007-11 18

Table 4: G8 pharmaceuticals industry forecast, revenue by country ($bn), 2011-16 19

Table 5: Canada pharmaceuticals market value: $ billion, 2007–11 21

Table 6: Canada pharmaceuticals market geography segmentation: $ billion, 2011 22

Table 7: Canada pharmaceuticals market share: % share, by value, 2011 23

Table 8: Canada pharmaceuticals market value forecast: $ billion, 2011–16 24

Table 9: Canada size of population (million), 2007–11 33

Table 10: Canada gdp (constant 2000 prices, $ billion), 2007–11 33

Table 11: Canada gdp (current prices, $ billion), 2007–11 33

Table 12: Canada inflation, 2007–11 34

Table 13: Canada consumer price index (absolute), 2007–11 34

Table 14: Canada exchange rate, 2007–11 34

Table 15: France pharmaceuticals market value: $ billion, 2007–11 36

Table 16: France pharmaceuticals market geography segmentation: $ billion, 2011 37

Table 17: France pharmaceuticals market share: % share, by value, 2011 38

Table 18: France pharmaceuticals market value forecast: $ billion, 2011–16 39

Table 19: France size of population (million), 2007–11 48

Table 20: France gdp (constant 2000 prices, $ billion), 2007–11 48

Table 21: France gdp (current prices, $ billion), 2007–11 48

Table 22: France inflation, 2007–11 49

Table 23: France consumer price index (absolute), 2007–11 49

Table 24: France exchange rate, 2007–11 49

Table 25: Germany pharmaceuticals market value: $ billion, 2007–11 51

Table 26: Germany pharmaceuticals market geography segmentation: $ billion, 2011 52

Table 27: Germany pharmaceuticals market share: % share, by value, 2011 53

Table 28: Germany pharmaceuticals market value forecast: $ billion, 2011–16 54

Table 29: Germany size of population (million), 2007–11 63

Table 30: Germany gdp (constant 2000 prices, $ billion), 2007–11 63

Table 31: Germany gdp (current prices, $ billion), 2007–11 63

Table 32: Germany inflation, 2007–11 64

Table 33: Germany consumer price index (absolute), 2007–11 64

Table 34: Germany exchange rate, 2007–11 64

Table 35: Italy pharmaceuticals market value: $ billion, 2007–11 66

Table 36: Italy pharmaceuticals market geography segmentation: $ billion, 2011 67

Table 37: Italy pharmaceuticals market share: % share, by value, 2011 68

Table 38: Italy pharmaceuticals market value forecast: $ billion, 2011–16 69

Table 39: Italy size of population (million), 2007–11 78

Table 40: Italy gdp (constant 2000 prices, $ billion), 2007–11 78

Table 41: Italy gdp (current prices, $ billion), 2007–11 78

Table 42: Italy inflation, 2007–11 79

Table 43: Italy consumer price index (absolute), 2007–11 79

Table 44: Italy exchange rate, 2007–11 79

Table 45: Japan pharmaceuticals market value: $ billion, 2007–11 81

Table 46: Japan pharmaceuticals market geography segmentation: $ billion, 2011 82

Table 47: Japan pharmaceuticals market share: % share, by value, 2011 83

Table 48: Japan pharmaceuticals market value forecast: $ billion, 2011–16 84

Table 49: Japan size of population (million), 2007–11 93

Table 50: Japan gdp (constant 2000 prices, $ billion), 2007–11 93

Table 51: Japan gdp (current prices, $ billion), 2007–11 93

Table 52: Japan inflation, 2007–11 94

Table 53: Japan consumer price index (absolute), 2007–11 94

Table 54: Japan exchange rate, 2007–11 94

Table 55: Russia pharmaceuticals market value: $ billion, 2007–11 96

Table 56: Russia pharmaceuticals market geography segmentation: $ billion, 2011 97

Table 57: Russia pharmaceuticals market share: % share, by value, 2011 98

Table 58: Russia pharmaceuticals market value forecast: $ billion, 2011–16 99

Table 59: Russia size of population (million), 2007–11 108

Table 60: Russia gdp (constant 2000 prices, $ billion), 2007–11 108

Table 61: Russia gdp (current prices, $ billion), 2007–11 108

Table 62: Russia inflation, 2007–11 109

Table 63: Russia consumer price index (absolute), 2007–11 109

Table 64: Russia exchange rate, 2007–11 109

Table 65: United Kingdom pharmaceuticals market value: $ billion, 2007–11 111

Table 66: United Kingdom pharmaceuticals market geography segmentation: $ billion, 2011 112

Table 67: United Kingdom pharmaceuticals market share: % share, by value, 2011 113

Table 68: United Kingdom pharmaceuticals market value forecast: $ billion, 2011–16 114

Table 69: United Kingdom size of population (million), 2007–11 123

Table 70: United Kingdom gdp (constant 2000 prices, $ billion), 2007–11 123

Table 71: United Kingdom gdp (current prices, $ billion), 2007–11 123

Table 72: United Kingdom inflation, 2007–11 124

Table 73: United Kingdom consumer price index (absolute), 2007–11 124

Table 74: United Kingdom exchange rate, 2007–11 124

Table 75: United States pharmaceuticals market value: $ billion, 2007–11 126

Table 76: United States pharmaceuticals market geography segmentation: $ billion, 2011 127

Table 77: United States pharmaceuticals market share: % share, by value, 2011 128

Table 78: United States pharmaceuticals market value forecast: $ billion, 2011–16 129

Table 79: United States size of population (million), 2007–11 138

Table 80: United States gdp (constant 2000 prices, $ billion), 2007–11 138

Table 81: United States gdp (current prices, $ billion), 2007–11 138

Table 82: United States inflation, 2007–11 139

Table 83: United States consumer price index (absolute), 2007–11 139

Table 84: United States exchange rate, 2007–11 139

Table 85: Johnson & Johnson: key facts 140

Table 86: Johnson & Johnson: key financials ($) 141

Table 87: Johnson & Johnson: key financial ratios 141

Table 88: Pfizer Inc.: key facts 143

Table 89: Pfizer Inc.: key financials ($) 144

Table 90: Pfizer Inc.: key financial ratios 144

Table 91: AstraZeneca PLC: key facts 146

Table 92: AstraZeneca PLC: key financials ($) 147

Table 93: AstraZeneca PLC: key financial ratios 148

Table 94: GlaxoSmithKline Plc: key facts 150

Table 95: GlaxoSmithKline Plc: key financials ($) 151

Table 96: GlaxoSmithKline Plc: key financials (£) 152

Table 97: GlaxoSmithKline Plc: key financial ratios 152

Table 98: Novartis AG: key facts 154

Table 99: Novartis AG: key financials ($) 155

Table 100: Novartis AG: key financial ratios 155

Table 101: Chiesi Farmaceutici S.P.A.: key facts 157

Table 102: Menarini Group, The: key facts 159

Table 103: Takeda Pharmaceutical Company Limited: key facts 160

Table 104: Takeda Pharmaceutical Company Limited: key financials ($) 161

Table 105: Takeda Pharmaceutical Company Limited: key financials (¥) 161

Table 106: Takeda Pharmaceutical Company Limited: key financial ratios 161

Table 107: Daiichi Sankyo Co., Ltd.: key facts 163

Table 108: Daiichi Sankyo Co., Ltd.: key financials ($) 164

Table 109: Daiichi Sankyo Co., Ltd.: key financials (¥) 164

Table 110: Daiichi Sankyo Co., Ltd.: key financial ratios 164

Table 111: Mitsubishi Tanabe Pharma Corporation: key facts 166

Table 112: Mitsubishi Tanabe Pharma Corporation: key financials ($) 167

Table 113: Mitsubishi Tanabe Pharma Corporation: key financials (¥) 167

Table 114: Mitsubishi Tanabe Pharma Corporation: key financial ratios 167

Table 115: Pharmstandard OJSC: key facts 169

Table 116: Pharmstandard OJSC: key financials ($) 169

Table 117: Pharmstandard OJSC: key financials (RUB) 170

Table 118: Pharmstandard OJSC: key financial ratios 170

Table 119: Sanofi: key facts 172

Table 120: Sanofi: key financials ($) 173

Table 121: Sanofi: key financials (€) 173

Table 122: Sanofi: key financial ratios 173

Table 123: Bayer AG: key facts 175

Table 124: Bayer AG: key financials ($) 176

Table 125: Bayer AG: key financials (€) 176

Table 126: Bayer AG: key financial ratios 177

Table 127: Merck & Co., Inc.: key facts 179

Table 128: Merck & Co., Inc.: key financials ($) 180

Table 129: Merck & Co., Inc.: key financial ratios 180

LIST OF FIGURESFigure 1: G8 pharmaceuticals industry, revenue($bn), 2007-16 15Figure 2: G8 pharmaceuticals industry, revenue by country ($bn), 2007-11 17Figure 3: G8 pharmaceuticals industry forecast, revenue by country ($bn), 2011-16 18Figure 4: Canada pharmaceuticals market value: $ billion, 2007–11 20Figure 5: Canada pharmaceuticals market geography segmentation: % share, by value, 2011 21Figure 6: Canada pharmaceuticals market share: % share, by value, 2011 22Figure 7: Canada pharmaceuticals market value forecast: $ billion, 2011–16 23Figure 8: Forces driving competition in the pharmaceuticals market in Canada, 2011 24Figure 9: Drivers of buyer power in the pharmaceuticals market in Canada, 2011 25Figure 10: Drivers of supplier power in the pharmaceuticals market in Canada, 2011 27Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2011 28Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2011 30Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2011 31Figure 14: France pharmaceuticals market value: $ billion, 2007–11 35Figure 15: France pharmaceuticals market geography segmentation: % share, by value, 2011 36Figure 16: France pharmaceuticals market share: % share, by value, 2011 37Figure 17: France pharmaceuticals market value forecast: $ billion, 2011–16 38Figure 18: Forces driving competition in the pharmaceuticals market in France, 2011 39Figure 19: Drivers of buyer power in the pharmaceuticals market in France, 2011 40Figure 20: Drivers of supplier power in the pharmaceuticals market in France, 2011 42Figure 21: Factors influencing the likelihood of new entrants in the pharmaceuticals market in France, 2011 43Figure 22: Factors influencing the threat of substitutes in the pharmaceuticals market in France, 2011 45Figure 23: Drivers of degree of rivalry in the pharmaceuticals market in France, 2011 46Figure 24: Germany pharmaceuticals market value: $ billion, 2007–11 50Figure 25: Germany pharmaceuticals market geography segmentation: % share, by value, 2011 51Figure 26: Germany pharmaceuticals market share: % share, by value, 2011 52Figure 27: Germany pharmaceuticals market value forecast: $ billion, 2011–16 53Figure 28: Forces driving competition in the pharmaceuticals market in Germany, 2011 54Figure 29: Drivers of buyer power in the pharmaceuticals market in Germany, 2011 55Figure 30: Drivers of supplier power in the pharmaceuticals market in Germany, 2011 57Figure 31: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Germany, 2011 58Figure 32: Factors influencing the threat of substitutes in the pharmaceuticals market in Germany, 2011 60Figure 33: Drivers of degree of rivalry in the pharmaceuticals market in Germany, 2011 61Figure 34: Italy pharmaceuticals market value: $ billion, 2007–11 65Figure 35: Italy pharmaceuticals market geography segmentation: % share, by value, 2011 66Figure 36: Italy pharmaceuticals market share: % share, by value, 2011 67Figure 37: Italy pharmaceuticals market value forecast: $ billion, 2011–16 68Figure 38: Forces driving competition in the pharmaceuticals market in Italy, 2011 69Figure 39: Drivers of buyer power in the pharmaceuticals market in Italy, 2011 70Figure 40: Drivers of supplier power in the pharmaceuticals market in Italy, 2011 72Figure 41: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Italy, 2011 73Figure 42: Factors influencing the threat of substitutes in the pharmaceuticals market in Italy, 2011 75Figure 43: Drivers of degree of rivalry in the pharmaceuticals market in Italy, 2011 76Figure 44: Japan pharmaceuticals market value: $ billion, 2007–11 80Figure 45: Japan pharmaceuticals market geography segmentation: % share, by value, 2011 81Figure 46: Japan pharmaceuticals market share: % share, by value, 2011 82Figure 47: Japan pharmaceuticals market value forecast: $ billion, 2011–16 83Figure 48: Forces driving competition in the pharmaceuticals market in Japan, 2011 84Figure 49: Drivers of buyer power in the pharmaceuticals market in Japan, 2011 85Figure 50: Drivers of supplier power in the pharmaceuticals market in Japan, 2011 87Figure 51: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Japan, 2011 88Figure 52: Factors influencing the threat of substitutes in the pharmaceuticals market in Japan, 2011 90Figure 53: Drivers of degree of rivalry in the pharmaceuticals market in Japan, 2011 91Figure 54: Russia pharmaceuticals market value: $ billion, 2007–11 95Figure 55: Russia pharmaceuticals market geography segmentation: % share, by value, 2011 96Figure 56: Russia pharmaceuticals market share: % share, by value, 2011 97Figure 57: Russia pharmaceuticals market value forecast: $ billion, 2011–16 98Figure 58: Forces driving competition in the pharmaceuticals market in Russia, 2011 99Figure 59: Drivers of buyer power in the pharmaceuticals market in Russia, 2011 100Figure 60: Drivers of supplier power in the pharmaceuticals market in Russia, 2011 102Figure 61: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Russia, 2011 103Figure 62: Factors influencing the threat of substitutes in the pharmaceuticals market in Russia, 2011 105Figure 63: Drivers of degree of rivalry in the pharmaceuticals market in Russia, 2011 106Figure 64: United Kingdom pharmaceuticals market value: $ billion, 2007–11 110Figure 65: United Kingdom pharmaceuticals market geography segmentation: % share, by value, 2011 111Figure 66: United Kingdom pharmaceuticals market share: % share, by value, 2011 112Figure 67: United Kingdom pharmaceuticals market value forecast: $ billion, 2011–16 113Figure 68: Forces driving competition in the pharmaceuticals market in the United Kingdom, 2011 114Figure 69: Drivers of buyer power in the pharmaceuticals market in the United Kingdom, 2011 115Figure 70: Drivers of supplier power in the pharmaceuticals market in the United Kingdom, 2011 117Figure 71: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United Kingdom, 2011 118Figure 72: Factors influencing the threat of substitutes in the pharmaceuticals market in the United Kingdom, 2011 120Figure 73: Drivers of degree of rivalry in the pharmaceuticals market in the United Kingdom, 2011 121Figure 74: United States pharmaceuticals market value: $ billion, 2007–11 125Figure 75: United States pharmaceuticals market geography segmentation: % share, by value, 2011 126Figure 76: United States pharmaceuticals market share: % share, by value, 2011 127Figure 77: United States pharmaceuticals market value forecast: $ billion, 2011–16 128Figure 78: Forces driving competition in the pharmaceuticals market in the United States, 2011 129Figure 79: Drivers of buyer power in the pharmaceuticals market in the United States, 2011 130Figure 80: Drivers of supplier power in the pharmaceuticals market in the United States, 2011 132Figure 81: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2011 133Figure 82: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2011 135Figure 83: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2011 136Figure 84: Johnson & Johnson: revenues & profitability 140Figure 85: Johnson & Johnson: assets & liabilities 141Figure 86: Pfizer Inc.: revenues & profitability 144Figure 87: Pfizer Inc.: assets & liabilities 144Figure 88: AstraZeneca PLC: revenues & profitability 147Figure 89: AstraZeneca PLC: assets & liabilities 148Figure 90: GlaxoSmithKline Plc: revenues & profitability 151Figure 91: GlaxoSmithKline Plc: assets & liabilities 152Figure 92: Novartis AG: revenues & profitability 155Figure 93: Novartis AG: assets & liabilities 155Figure 94: Takeda Pharmaceutical Company Limited: revenues & profitability 161Figure 95: Takeda Pharmaceutical Company Limited: assets & liabilities 161Figure 96: Daiichi Sankyo Co., Ltd.: revenues & profitability 164Figure 97: Daiichi Sankyo Co., Ltd.: assets & liabilities 164Figure 98: Mitsubishi Tanabe Pharma Corporation: revenues & profitability 167Figure 99: Mitsubishi Tanabe Pharma Corporation: assets & liabilities 167Figure 100: Pharmstandard OJSC: revenues & profitability 169Figure 101: Pharmstandard OJSC: assets & liabilities 170Figure 102: Sanofi: revenues & profitability 173Figure 103: Sanofi: assets & liabilities 173Figure 104: Bayer AG: revenues & profitability 176Figure 105: Bayer AG: assets & liabilities 177Figure 106: Merck & Co., Inc.: revenues & profitability 179Figure 107: Merck & Co., Inc.: assets & liabilities 180

To order this report:Pharmaceutical Industry: Pharmaceuticals - Global Group of Eight (G8) Industry Guide

Nicolas Bombourg

Reportlinker

Email: nicolasbombourg@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.